Search results
Results from the WOW.Com Content Network
Amoxicillin and doxycycline are suitable for many of the lower respiratory tract infections seen in general practice. [21] Another cochrane review suggests that new studies are needed to confirm that azithromycin may lead to less treatment failure and lower side effects than amoxycillin. [ 24 ]
In the UK, treatment before culture results with amoxicillin is recommended as the first line for community-acquired pneumonia, with doxycycline or clarithromycin as alternatives. [69] In North America, amoxicillin, doxycycline, and in some areas a macrolide (such as azithromycin or erythromycin) is the first-line outpatient treatment in adults.
Atypical bacteria causing pneumonia are Coxiella burnetii, Chlamydophila pneumoniae (), Mycoplasma pneumoniae (), and Legionella pneumophila.. The term "atypical" does not relate to how commonly these organisms cause pneumonia, how well it responds to common antibiotics or how typical the symptoms are; it refers instead to the fact that these organisms have atypical or absent cell wall ...
Doxycycline is a broad-spectrum antibiotic of the tetracycline class used in the treatment of infections caused by bacteria and certain parasites. [1] It is used to treat bacterial pneumonia , acne , chlamydia infections , Lyme disease , cholera , typhus , and syphilis . [ 1 ]
Amoxicillin (α-amino-p-hydroxybenzyl penicillin) is a semisynthetic derivative of penicillin with a structure similar to ampicillin but with better absorption when taken by mouth, thus yielding higher concentrations in blood and in urine. [58] Amoxicillin diffuses easily into tissues and body fluids.
Pneumococcal pneumonia is a type of bacterial pneumonia that is caused by Streptococcus pneumoniae (pneumococcus). [1] It is the most common bacterial pneumonia found in adults, the most common type of community-acquired pneumonia, and one of the common types of pneumococcal infection. The estimated number of Americans with pneumococcal ...
Mayo Clinic has reached a deal to sell its ownership stake in a medical center in Abu Dhabi, reportedly for about $150 million. Reuters first reported on the transaction and purchase price this week.
Narrow-spectrum antibiotics have low propensity to induce bacterial resistance and are less likely to disrupt the microbiome (normal microflora). [3] On the other hand, indiscriminate use of broad-spectrum antibiotics may not only induce the development of bacterial resistance and promote the emergency of multidrug-resistant organisms, but also cause off-target effects due to dysbiosis.